Drug Trial Radar · NCT00312351
A Clinical Trial to Explore the Safety and Efficacy of Three Different Doses of Pegaptanib Sodium in Patients With Wet Age-Related Macular Degeneration (AMD)
Last checked: Nov 20, 2026Latest source record: Jan 15, 2007 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
262
Actual
Start
Apr 2006
Primary completion
Not stated
Study completion Nov 2006
Sponsor
- Lead sponsor
- Eyetech PharmaceuticalsIndustry
- Sponsor type
- Industry
- Collaborators
- Pfizer
- First posted
- Apr 10, 2006
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this trial is to compare the ability of three different doses of pegaptanib sodium to safely and effectively minimize fluid leakage within the eye, thereby stabilizing or improving vision in patients with wet AMD. The study will also examine the effects of pegaptanib sodium on the cornea and sensory retina of patients with wet AMD.
Conditions
- Macular Degeneration
Interventions
Pegaptanib sodiumDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
No primary outcomes listed.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Charlotte Eye, Ear, Nose and Throat Associates, P.A.
Charlotte, North Carolina
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.